Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer Interventions:   Drug: CA102N;   Drug: TAS-102;   Biological: Bevacizumab Sponsor:   Holy Stone Healthcare Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials